European CHMP Adopts Positive Opinion on Ondexxya™ (andexanet alfa) Portola Pharmaceuticals’ Factor Xa Inhibitor Reversal Agent
March 01, 2019 07:38 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding
February 07, 2019 16:03 ET
|
Portola Pharmaceuticals, Inc.
– Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients – –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events Observed Among Patients Who Re-started...
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019
February 01, 2019 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s...
Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019
January 30, 2019 08:43 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa®...
Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer
January 28, 2019 09:23 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief...
U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process
December 31, 2018 15:19 ET
|
Portola Pharmaceuticals, Inc.
– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban – – Full Commercial Launch to Begin January 2019 – SOUTH SAN...
Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019
December 18, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will...
CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa)
December 11, 2018 07:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
December 03, 2018 21:15 ET
|
Portola Pharmaceuticals, Inc.
– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant Reduction in Itching...
Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 07, 2018 16:05 ET
|
Portola Pharmaceuticals, Inc.
– Third Quarter Andexxa Product Revenues of $7.7 Million – – Company Improves Financial Expectations for 2018 Operating Expenses – – Conference Call Today at 4:30 p.m. ET – SOUTH SAN FRANCISCO,...